EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases
Objective Tyrosine kinase inhibitors (TKIs) is the first-line treatment for EGFR-positive non-small cell lung cancer (NSCLC); however, its applicability to patients with wild-type NSCLC remains an issue of contention. This study compared the effects of gamma knife radiosurgery (GKRS) alone versus co...
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-oncology 2022-09, Vol.159 (3), p.675-684 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 684 |
|---|---|
| container_issue | 3 |
| container_start_page | 675 |
| container_title | Journal of neuro-oncology |
| container_volume | 159 |
| creator | Liao, Hung-Ruei Chiang, Chi-Lu Shen, Chia-I. Chen, Ching-Jen Yang, Huai-Che Wu, Hsiu-Mei Luo, Yung-Hung Hu, Yong-Sin Lin, Chung-Jung Chung, Wen-Yuh Shiau, Cheng-Ying Guo, Wan-Yuo Pan, David Hung-Chi Lee, Cheng-Chia |
| description | Objective
Tyrosine kinase inhibitors (TKIs) is the first-line treatment for EGFR-positive non-small cell lung cancer (NSCLC); however, its applicability to patients with wild-type NSCLC remains an issue of contention. This study compared the effects of gamma knife radiosurgery (GKRS) alone versus combining GKRS and TKIs in treating two genetic forms of NSCLC.
Methods
This retrospective study examined 479 NSCLC patients with 1982 brain metastases who underwent GKRS and for whom imaging follow-up data or death records were available. All our patients were consecutive. All gene mutations were confirmed by lung biopsy. The three main endpoints in this study were overall survival (OS), local intracranial tumor control (LC), and distal intracranial tumor control (DC).
Results
There were 296 NSCLC patients with EGFR positive: TKI treatment (n = 262) and without TKI treatment (n = 34). GKRS + TKIs was more effective than GKRS alone in terms of OS (HR 0.53, p = 0.085) and DC (HR 0.51, p |
| doi_str_mv | 10.1007/s11060-022-04110-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2703416489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2714784306</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-72cfde9be1db4a86b949071c69c4b19c15a8c5104b0f331ee60b0de8838ea8da3</originalsourceid><addsrcrecordid>eNp9kMFKxDAQhoMouK6-gKeAFy_RSZNt0qMsuoqLgqvgLaTpVKvbVJP04NsbXUHw4GkG5vt_ho-QQw4nHECdRs6hBAZFwUDmnektMuEzJZgSSmyTCfBSsVklH3fJXowvACCV4BOC54uLO9qPyfpEY7JpjNT6hqaPMMTOI3vtvI1IO__c1V0aQj63LbpE0zPSxfXdig5jckOPkbZDoDer-XJO62A7T3tMNldGjPtkp7XriAc_c0oeLs7v55dsebu4mp8tmRNVmZgqXNtgVSNvaml1WVeyAsVdWTlZ88rxmdVuxkHW0ArBEUuooUGthUarGyum5HjT-xaG9xFjMn0XHa7X1uMwRlMoEJKXUlcZPfqDvgxj8Pm7THGptBRQZqrYUC7riAFb8xa63oYPw8F8mTcb8yabN9_mjc4hsQnFDPsnDL_V_6Q-AQZQhic</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2714784306</pqid></control><display><type>article</type><title>EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases</title><source>SpringerLink Journals - AutoHoldings</source><creator>Liao, Hung-Ruei ; Chiang, Chi-Lu ; Shen, Chia-I. ; Chen, Ching-Jen ; Yang, Huai-Che ; Wu, Hsiu-Mei ; Luo, Yung-Hung ; Hu, Yong-Sin ; Lin, Chung-Jung ; Chung, Wen-Yuh ; Shiau, Cheng-Ying ; Guo, Wan-Yuo ; Pan, David Hung-Chi ; Lee, Cheng-Chia</creator><creatorcontrib>Liao, Hung-Ruei ; Chiang, Chi-Lu ; Shen, Chia-I. ; Chen, Ching-Jen ; Yang, Huai-Che ; Wu, Hsiu-Mei ; Luo, Yung-Hung ; Hu, Yong-Sin ; Lin, Chung-Jung ; Chung, Wen-Yuh ; Shiau, Cheng-Ying ; Guo, Wan-Yuo ; Pan, David Hung-Chi ; Lee, Cheng-Chia</creatorcontrib><description>Objective
Tyrosine kinase inhibitors (TKIs) is the first-line treatment for EGFR-positive non-small cell lung cancer (NSCLC); however, its applicability to patients with wild-type NSCLC remains an issue of contention. This study compared the effects of gamma knife radiosurgery (GKRS) alone versus combining GKRS and TKIs in treating two genetic forms of NSCLC.
Methods
This retrospective study examined 479 NSCLC patients with 1982 brain metastases who underwent GKRS and for whom imaging follow-up data or death records were available. All our patients were consecutive. All gene mutations were confirmed by lung biopsy. The three main endpoints in this study were overall survival (OS), local intracranial tumor control (LC), and distal intracranial tumor control (DC).
Results
There were 296 NSCLC patients with EGFR positive: TKI treatment (n = 262) and without TKI treatment (n = 34). GKRS + TKIs was more effective than GKRS alone in terms of OS (HR 0.53, p = 0.085) and DC (HR 0.51, p < 0.001). There were 150 NSCLC patients with wild-type EGFR: TKI treatment (n = 50) and without TKI treatment (n = 100). GKRS + TKIs was less effective than GKRS alone in terms of OS (HR 1.82, p = 0.049) and DC (HR: 1.40, p = 0.011). We observed no difference in terms of LC in both genetic groups.
Conclusions
Combining GKRS with TKIs proved effective in EGFR positive NSCLC patients; however, we do not observe the similar results when combining GKRS with TKIs for patients with wild-type NSCLC.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-022-04110-8</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biopsy ; Brain cancer ; Epidermal growth factor receptors ; Lung cancer ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Neuroimaging ; Neurology ; Non-small cell lung carcinoma ; Oncology ; Patients ; Radiosurgery ; Small cell lung carcinoma ; Tumors ; Tyrosine kinase inhibitors</subject><ispartof>Journal of neuro-oncology, 2022-09, Vol.159 (3), p.675-684</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-72cfde9be1db4a86b949071c69c4b19c15a8c5104b0f331ee60b0de8838ea8da3</citedby><cites>FETCH-LOGICAL-c396t-72cfde9be1db4a86b949071c69c4b19c15a8c5104b0f331ee60b0de8838ea8da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11060-022-04110-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11060-022-04110-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids></links><search><creatorcontrib>Liao, Hung-Ruei</creatorcontrib><creatorcontrib>Chiang, Chi-Lu</creatorcontrib><creatorcontrib>Shen, Chia-I.</creatorcontrib><creatorcontrib>Chen, Ching-Jen</creatorcontrib><creatorcontrib>Yang, Huai-Che</creatorcontrib><creatorcontrib>Wu, Hsiu-Mei</creatorcontrib><creatorcontrib>Luo, Yung-Hung</creatorcontrib><creatorcontrib>Hu, Yong-Sin</creatorcontrib><creatorcontrib>Lin, Chung-Jung</creatorcontrib><creatorcontrib>Chung, Wen-Yuh</creatorcontrib><creatorcontrib>Shiau, Cheng-Ying</creatorcontrib><creatorcontrib>Guo, Wan-Yuo</creatorcontrib><creatorcontrib>Pan, David Hung-Chi</creatorcontrib><creatorcontrib>Lee, Cheng-Chia</creatorcontrib><title>EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><description>Objective
Tyrosine kinase inhibitors (TKIs) is the first-line treatment for EGFR-positive non-small cell lung cancer (NSCLC); however, its applicability to patients with wild-type NSCLC remains an issue of contention. This study compared the effects of gamma knife radiosurgery (GKRS) alone versus combining GKRS and TKIs in treating two genetic forms of NSCLC.
Methods
This retrospective study examined 479 NSCLC patients with 1982 brain metastases who underwent GKRS and for whom imaging follow-up data or death records were available. All our patients were consecutive. All gene mutations were confirmed by lung biopsy. The three main endpoints in this study were overall survival (OS), local intracranial tumor control (LC), and distal intracranial tumor control (DC).
Results
There were 296 NSCLC patients with EGFR positive: TKI treatment (n = 262) and without TKI treatment (n = 34). GKRS + TKIs was more effective than GKRS alone in terms of OS (HR 0.53, p = 0.085) and DC (HR 0.51, p < 0.001). There were 150 NSCLC patients with wild-type EGFR: TKI treatment (n = 50) and without TKI treatment (n = 100). GKRS + TKIs was less effective than GKRS alone in terms of OS (HR 1.82, p = 0.049) and DC (HR: 1.40, p = 0.011). We observed no difference in terms of LC in both genetic groups.
Conclusions
Combining GKRS with TKIs proved effective in EGFR positive NSCLC patients; however, we do not observe the similar results when combining GKRS with TKIs for patients with wild-type NSCLC.</description><subject>Biopsy</subject><subject>Brain cancer</subject><subject>Epidermal growth factor receptors</subject><subject>Lung cancer</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Neuroimaging</subject><subject>Neurology</subject><subject>Non-small cell lung carcinoma</subject><subject>Oncology</subject><subject>Patients</subject><subject>Radiosurgery</subject><subject>Small cell lung carcinoma</subject><subject>Tumors</subject><subject>Tyrosine kinase inhibitors</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kMFKxDAQhoMouK6-gKeAFy_RSZNt0qMsuoqLgqvgLaTpVKvbVJP04NsbXUHw4GkG5vt_ho-QQw4nHECdRs6hBAZFwUDmnektMuEzJZgSSmyTCfBSsVklH3fJXowvACCV4BOC54uLO9qPyfpEY7JpjNT6hqaPMMTOI3vtvI1IO__c1V0aQj63LbpE0zPSxfXdig5jckOPkbZDoDer-XJO62A7T3tMNldGjPtkp7XriAc_c0oeLs7v55dsebu4mp8tmRNVmZgqXNtgVSNvaml1WVeyAsVdWTlZ88rxmdVuxkHW0ArBEUuooUGthUarGyum5HjT-xaG9xFjMn0XHa7X1uMwRlMoEJKXUlcZPfqDvgxj8Pm7THGptBRQZqrYUC7riAFb8xa63oYPw8F8mTcb8yabN9_mjc4hsQnFDPsnDL_V_6Q-AQZQhic</recordid><startdate>20220901</startdate><enddate>20220901</enddate><creator>Liao, Hung-Ruei</creator><creator>Chiang, Chi-Lu</creator><creator>Shen, Chia-I.</creator><creator>Chen, Ching-Jen</creator><creator>Yang, Huai-Che</creator><creator>Wu, Hsiu-Mei</creator><creator>Luo, Yung-Hung</creator><creator>Hu, Yong-Sin</creator><creator>Lin, Chung-Jung</creator><creator>Chung, Wen-Yuh</creator><creator>Shiau, Cheng-Ying</creator><creator>Guo, Wan-Yuo</creator><creator>Pan, David Hung-Chi</creator><creator>Lee, Cheng-Chia</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20220901</creationdate><title>EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases</title><author>Liao, Hung-Ruei ; Chiang, Chi-Lu ; Shen, Chia-I. ; Chen, Ching-Jen ; Yang, Huai-Che ; Wu, Hsiu-Mei ; Luo, Yung-Hung ; Hu, Yong-Sin ; Lin, Chung-Jung ; Chung, Wen-Yuh ; Shiau, Cheng-Ying ; Guo, Wan-Yuo ; Pan, David Hung-Chi ; Lee, Cheng-Chia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-72cfde9be1db4a86b949071c69c4b19c15a8c5104b0f331ee60b0de8838ea8da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biopsy</topic><topic>Brain cancer</topic><topic>Epidermal growth factor receptors</topic><topic>Lung cancer</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Neuroimaging</topic><topic>Neurology</topic><topic>Non-small cell lung carcinoma</topic><topic>Oncology</topic><topic>Patients</topic><topic>Radiosurgery</topic><topic>Small cell lung carcinoma</topic><topic>Tumors</topic><topic>Tyrosine kinase inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liao, Hung-Ruei</creatorcontrib><creatorcontrib>Chiang, Chi-Lu</creatorcontrib><creatorcontrib>Shen, Chia-I.</creatorcontrib><creatorcontrib>Chen, Ching-Jen</creatorcontrib><creatorcontrib>Yang, Huai-Che</creatorcontrib><creatorcontrib>Wu, Hsiu-Mei</creatorcontrib><creatorcontrib>Luo, Yung-Hung</creatorcontrib><creatorcontrib>Hu, Yong-Sin</creatorcontrib><creatorcontrib>Lin, Chung-Jung</creatorcontrib><creatorcontrib>Chung, Wen-Yuh</creatorcontrib><creatorcontrib>Shiau, Cheng-Ying</creatorcontrib><creatorcontrib>Guo, Wan-Yuo</creatorcontrib><creatorcontrib>Pan, David Hung-Chi</creatorcontrib><creatorcontrib>Lee, Cheng-Chia</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liao, Hung-Ruei</au><au>Chiang, Chi-Lu</au><au>Shen, Chia-I.</au><au>Chen, Ching-Jen</au><au>Yang, Huai-Che</au><au>Wu, Hsiu-Mei</au><au>Luo, Yung-Hung</au><au>Hu, Yong-Sin</au><au>Lin, Chung-Jung</au><au>Chung, Wen-Yuh</au><au>Shiau, Cheng-Ying</au><au>Guo, Wan-Yuo</au><au>Pan, David Hung-Chi</au><au>Lee, Cheng-Chia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><date>2022-09-01</date><risdate>2022</risdate><volume>159</volume><issue>3</issue><spage>675</spage><epage>684</epage><pages>675-684</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>Objective
Tyrosine kinase inhibitors (TKIs) is the first-line treatment for EGFR-positive non-small cell lung cancer (NSCLC); however, its applicability to patients with wild-type NSCLC remains an issue of contention. This study compared the effects of gamma knife radiosurgery (GKRS) alone versus combining GKRS and TKIs in treating two genetic forms of NSCLC.
Methods
This retrospective study examined 479 NSCLC patients with 1982 brain metastases who underwent GKRS and for whom imaging follow-up data or death records were available. All our patients were consecutive. All gene mutations were confirmed by lung biopsy. The three main endpoints in this study were overall survival (OS), local intracranial tumor control (LC), and distal intracranial tumor control (DC).
Results
There were 296 NSCLC patients with EGFR positive: TKI treatment (n = 262) and without TKI treatment (n = 34). GKRS + TKIs was more effective than GKRS alone in terms of OS (HR 0.53, p = 0.085) and DC (HR 0.51, p < 0.001). There were 150 NSCLC patients with wild-type EGFR: TKI treatment (n = 50) and without TKI treatment (n = 100). GKRS + TKIs was less effective than GKRS alone in terms of OS (HR 1.82, p = 0.049) and DC (HR: 1.40, p = 0.011). We observed no difference in terms of LC in both genetic groups.
Conclusions
Combining GKRS with TKIs proved effective in EGFR positive NSCLC patients; however, we do not observe the similar results when combining GKRS with TKIs for patients with wild-type NSCLC.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s11060-022-04110-8</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 2022-09, Vol.159 (3), p.675-684 |
| issn | 0167-594X 1573-7373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2703416489 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Biopsy Brain cancer Epidermal growth factor receptors Lung cancer Medicine Medicine & Public Health Metastases Metastasis Neuroimaging Neurology Non-small cell lung carcinoma Oncology Patients Radiosurgery Small cell lung carcinoma Tumors Tyrosine kinase inhibitors |
| title | EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T12%3A07%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EGFR%20mutant%20status%20and%20tyrosine-kinase%20inhibitors%20affect%20the%20GKRS%20outcomes%20for%20NSCLC%20brain%20metastases&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Liao,%20Hung-Ruei&rft.date=2022-09-01&rft.volume=159&rft.issue=3&rft.spage=675&rft.epage=684&rft.pages=675-684&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-022-04110-8&rft_dat=%3Cproquest_cross%3E2714784306%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2714784306&rft_id=info:pmid/&rfr_iscdi=true |